April 23, 2010 at 17:45 PM EDT
Glitches Hinder OKs For Human Genome
If you had a choice between two medications that performed almost identically, but one required a weekly injection and the other required an injection every two weeks, which would you prefer? On the face of it, the answer is obvious. That's the decision Human Genome Sciences (HGSI) hopes patients and physicians make, if and when the company's hepatitis C drug, Zalbin, gets Food and Drug Administration approval. "The convenience factor is
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here